Brief: Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals Identified
BRIEF-Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals Identified Oct 2 (Reuters) - Biogen Inc. BIIB.O:
BIOGEN’S LITIFILIMAB DEMONSTRATES RAPID AND DURABLE EFFICACY IN NEW 52-WEEK PHASE 2 DATA FROM ONGOING PHASE 2/3 AMETHYST STUDY, REINFORCING ITS POTENTIAL AS A FIRST-IN-CLASS THERAPY FOR CUTANEOUS LUPUS ERYTHEMATOSUS~
BIOGEN - 27.2% OF PARTICIPANTS ACHIEVE CLEAR OR ALMOST CLEAR SKIN AT WEEK 52 WITH LITIFILIMAB
BIOGEN - LITIFILIMAB SAFETY PROFILE REMAINS CONSISTENT WITH NO NEW SAFETY SIGNALS IDENTIFIED
BIOGEN - SERIOUS ADVERSE EVENTS OCCURRED IN 3.4% OF PARTICIPANTS DURING 52-WEEK TREATMENT PERIOD
BIOGEN - 28.8% OF PARTICIPANTS ACHIEVE 70% OR GREATER REDUCTION IN CLASI A AT WEEK 52
BIOGEN - 33.7% OF CROSSOVER PARTICIPANTS REPORT CLEAR OR ALMOST CLEAR SKIN AT WEEK 52
Source text: ID:nGNX674631
Further company coverage: BIIB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova